Study · Randomized controlled trial · n = 30 · 2017

8 results

GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.

Pastel E, McCulloch LJ, Ward R, Joshi S, Gooding KM, Shore AC, Kos K

Clinical science (London, England : 1979)3 Jan 2017Cited by 42 (Europe PMC)

PMID28049736DOI10.1042/cs20160803PepBankPUB-28049736

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide lowered fasting glucose more than weight loss by calorie restriction.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered fasting glucose more than dieting did.
Peptide
Liraglutide
Outcome
DecreaseFasting glucose
Study
n = 30
Comparator
Calorie restriction
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 4 monthsAs given in this study (human).
Source sentences
Summary
It was more effective in lowering fasting glucose, in comparison with weight loss by dieting.
1 context sentence(design, population, supporting numbers)
Summary · context
Among the 39 participants with Type 2 diabetes recruited, 30 age-matched participants were randomized to 4 months treatment with Liraglutide (n=22) or calorie restriction based on dietetic counselling (n=8).
Report a problemFND-2804973603
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, 4 months of liraglutide reduced body weight.
In plain wordsIn adults with type 2 diabetes, liraglutide treatment for 4 months led to weight loss.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 22
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 4 monthsAs given in this study (human).
Measurements
Body weight change
−3.12 kg
liraglutide
Source sentences
Summary
Liraglutide resulted in weight loss in most participants (-3.12±1.72 kg, P=0.007) and significant reduction in visceral AT (VAT).
1 context sentence(design, population, supporting numbers)
Summary · context
Among the 39 participants with Type 2 diabetes recruited, 30 age-matched participants were randomized to 4 months treatment with Liraglutide (n=22) or calorie restriction based on dietetic counselling (n=8).
Report a problemFND-2804973601
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide significantly reduced visceral adipose tissue.
In plain wordsIn adults with type 2 diabetes, liraglutide reduced fat around the organs.
Peptide
Liraglutide
Outcome
DecreaseVisceral adipose tissue
Study
n = 22
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 4 monthsAs given in this study (human).
Source sentences
Summary
Liraglutide resulted in weight loss in most participants (-3.12±1.72 kg, P=0.007) and significant reduction in visceral AT (VAT).
1 context sentence(design, population, supporting numbers)
Summary · context
Among the 39 participants with Type 2 diabetes recruited, 30 age-matched participants were randomized to 4 months treatment with Liraglutide (n=22) or calorie restriction based on dietetic counselling (n=8).
Report a problemFND-2804973602
04HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, liraglutide increased TNFA expression in subcutaneous adipose tissue.
In plain wordsIn adults with type 2 diabetes, liraglutide raised a fat tissue marker of inflammation (TNFA).
Peptide
Liraglutide
Outcome
IncreaseTNFA expression in subcutaneous adipose tissue
Study
n = 22
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 4 monthsAs given in this study (human).
Source sentences
Summary
However, tumour necrosis factor-α (TNFA) AT-expression (P=0.0005), macrophage chemoattractant protein-1 (MCP-1) expression (P=0.027) and its serum levels (P=0.048) increased with Liraglutide
1 context sentence(design, population, supporting numbers)
Summary · context
Among the 39 participants with Type 2 diabetes recruited, 30 age-matched participants were randomized to 4 months treatment with Liraglutide (n=22) or calorie restriction based on dietetic counselling (n=8).
Report a problemFND-2804973604
05HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, liraglutide increased MCP-1 expression in subcutaneous adipose tissue.
In plain wordsIn adults with type 2 diabetes, liraglutide raised a fat tissue marker of inflammation (MCP-1).
Peptide
Liraglutide
Outcome
IncreaseMCP-1 expression in subcutaneous adipose tissue
Study
n = 22
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 4 monthsAs given in this study (human).
Source sentences
Summary
However, tumour necrosis factor-α (TNFA) AT-expression (P=0.0005), macrophage chemoattractant protein-1 (MCP-1) expression (P=0.027) and its serum levels (P=0.048) increased with Liraglutide
1 context sentence(design, population, supporting numbers)
Summary · context
Among the 39 participants with Type 2 diabetes recruited, 30 age-matched participants were randomized to 4 months treatment with Liraglutide (n=22) or calorie restriction based on dietetic counselling (n=8).
Report a problemFND-2804973605
06HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, liraglutide increased serum MCP-1 levels.
In plain wordsIn adults with type 2 diabetes, liraglutide raised blood levels of the inflammation marker MCP-1.
Peptide
Liraglutide
Outcome
IncreaseSerum MCP-1
Study
n = 22
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 4 monthsAs given in this study (human).
Source sentences
Summary
However, tumour necrosis factor-α (TNFA) AT-expression (P=0.0005), macrophage chemoattractant protein-1 (MCP-1) expression (P=0.027) and its serum levels (P=0.048) increased with Liraglutide
1 context sentence(design, population, supporting numbers)
Summary · context
Among the 39 participants with Type 2 diabetes recruited, 30 age-matched participants were randomized to 4 months treatment with Liraglutide (n=22) or calorie restriction based on dietetic counselling (n=8).
Report a problemFND-2804973606
07HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, liraglutide increased expression of TGFB1, a factor of extracellular matrix deposition, in adipose tissue.
In plain wordsIn adults with type 2 diabetes, liraglutide increased fat tissue activity of TGFB1, a gene linked to tissue scarring.
Peptide
Liraglutide
Outcome
IncreaseTGFB1 expression in subcutaneous adipose tissue
Study
n = 22
Outcome group
Fat metabolism and adipogenesis · Metabolic and weight
Studied dose
Dose not stated · 4 monthsAs given in this study (human).
Measurements
TGFB1 expression
0.73 AU
before
TGFB1 expression
1 AU
after
Source sentences
Summary
Liraglutide treatment also increased expression of factors involved in extracellular matrix (ECM) deposition, transforming growth factor-β (TGFB) and collagen type 1 alpha 1 chain (COL1A1) (
2 context sentences(design, population, supporting numbers)
Summary · context
before 0.73±0.09 arbitrary units (AU), after 1.00±0.13 AU, P=0.006;
Summary · context
Among the 39 participants with Type 2 diabetes recruited, 30 age-matched participants were randomized to 4 months treatment with Liraglutide (n=22) or calorie restriction based on dietetic counselling (n=8).
Report a problemFND-2804973607
08HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, liraglutide increased expression of COL1A1, a factor of extracellular matrix deposition, in adipose tissue.
In plain wordsIn adults with type 2 diabetes, liraglutide increased fat tissue activity of COL1A1, a collagen gene.
Peptide
Liraglutide
Outcome
IncreaseCOL1A1 expression in subcutaneous adipose tissue
Study
n = 22
Outcome group
Fat metabolism and adipogenesis · Metabolic and weight
Studied dose
Dose not stated · 4 monthsAs given in this study (human).
Measurements
COL1A1 expression
0.84 AU
before
COL1A1 expression
1.49 AU
after
Source sentences
Summary
Liraglutide treatment also increased expression of factors involved in extracellular matrix (ECM) deposition, transforming growth factor-β (TGFB) and collagen type 1 alpha 1 chain (COL1A1) (
2 context sentences(design, population, supporting numbers)
Summary · context
0.84±0.09 AU compared with 1.49±0.26 AU, P=0.026).
Summary · context
Among the 39 participants with Type 2 diabetes recruited, 30 age-matched participants were randomized to 4 months treatment with Liraglutide (n=22) or calorie restriction based on dietetic counselling (n=8).
Report a problemFND-2804973608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT04122716

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet

Signe Torekovn = 215Sept 2016 to est. Nov 2021

Obesity

Trial page ClinicalTrials.govUpdated 2 Nov 2020

CompletedNot applicableNCT01740921

GLP-1 and Microvascular Function in Type 2 Diabetes

Royal Devon and Exeter NHS Foundation Trustn = 39Jan 2011 to Feb 2016

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 17 Feb 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.